Could immune cells slow ALS? new safety trial launches
NCT ID NCT06671236
First seen Nov 01, 2025 · Last updated May 03, 2026 · Updated 28 times
Summary
This study tests whether a new treatment using a person's own regulatory T cells (Tregs) is safe for people with amyotrophic lateral sclerosis (ALS), a progressive nerve disease. Twelve adults aged 18 to 70 with ALS will receive the cell infusion and be monitored for side effects and maximum tolerated dose. The goal is to see if this approach can control the disease without causing serious harm.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, Henan, 450052, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.